Download image:

Josephine A. Mauskopf

Vice President of Health Economics, RTI-HS

Josephine Mauskopf, PhD, MHA, has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf was previously vice president at MEDTAP International, department head of Economics Research at Burroughs Wellcome, and director of Pharmacoeconomics Research for anti-virals and anti-infectives at Glaxo Wellcome. She recently completed 8 years as editor in chief of Value in Health. She has presented her research at numerous national and international symposia, and has published extensively in journals.


PhD, Economics, Duke University; MHA, Health Administration, Duke University; MA, Physiology and Pharmacology, Duke University.

Latest Publications

Standaert, B., Ethgen, O., Emerson, R., Postma, M., & Mauskopf, J. (2014). Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn?. Advances in Therapy, 31 (10):1095-1108.
Brogan, A.J., Smets, E., Mauskopf, J.A., Manuel, S.A., & Adriaenssen, I. (2014). Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics, 32 (9):903-917.
Brennan, V.K., Colosia, A.D., Copley-Merriman, C., Mauskopf, J., Hass, B., & Palencia, R. (2014). Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: An overview for economic modeling. Journal of Medical Economics, 17 (7):469-480.
Mauskopf, J., Fay, M., Iyer, R., & Livingston, T. (2014). Budget Impact of Adding Delayed-Release Dimethyl Fumarate to the Formulary for the Treatment of Relapsing Forms of Multiple Sclerosis. Presented at ISPOR 19th Annual International Meeting, June 2014.
Mauskopf, J., Fay, M., Iyer, R., Sarda, S., & Livingston, T. (2014). Cost-effectiveness of Delayed-Release Dimethyl Fumarate Compared With Glatiramer Acetate and Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis. Presented at ISPOR 19th Annual International Meeting, June.
View all publications by Josephine A. Mauskopf (197)